Benefits of antihypertensive pharmacologic therapy and blood pressure reduction in outcome trials

Journal of Clinical Hypertension

Volumn 5, Issue 1, 2003, Pages 66-75

  Wang, Ji Guang ^a   Staessen, Jan A ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLOROTHIAZIDE; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ENALAPRIL; FELODIPINE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; ISRADIPINE; METHYCLOTHIAZIDE; NICARDIPINE; NIFEDIPINE; PERINDOPRIL; PLACEBO; PROPRANOLOL; RAMIPRIL; RESERPINE; SIMVASTATIN; THIAZIDE DIURETIC AGENT; TRIAMTERENE; UNINDEXED DRUG; VERAPAMIL;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOTHESIS; INCIDENCE; META ANALYSIS; MONOTHERAPY; PREDICTION; PROGNOSIS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REGRESSION ANALYSIS; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STROKE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 0037277966     PISSN: 15246175     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-6175.2003.01307.x     Document Type: Review

References (67)

1. Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet. 2000;355:865-872.
2. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull. 1994;50:272-298.
3. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755-1762.
4. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J. 1998;317:703-713.
5. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension. 1999;34:1129-1133.
6. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertensive Treatment (INSIGHT). Lancet. 2000;356:366-372.
7. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers; on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000;356:359-365.
8. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354:1751-1756.
9. Agabiti Rosei E, Dal Palù C, Leonetti G, et al. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. J Hypertens. 1997;15:1337-1344.
10. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension : the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611-616.
11. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J. 2000;317:713-720.
12. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2000;283:1967-1975.
13. Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation. 2000;102:1503-1510.
14. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
15. MacMahon S, Sharpe N, Gamble G, et al. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. J Am Coll Cardiol. 2000;36:438-443.
16. Teo KK, Burton JR, Buller CE, et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis. The Simvastatin/ Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation. 2000;102:1748-1754.
17. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a meta-analysis [published correction appears in Lancet. 2002 Jan 26;359:360]. Lancet. 2001;358:1305-1315.
18. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
19. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
20. Parving HH, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
21. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with prior stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041.
22. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. 1970; 213:1143-1152.
23. Hypertension-Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA. 1974;229:409-418.
24. Smith WM. Treatment of mild hypertension: results of a ten-year intervention trial. Circ Res. 1977;40:I98-I105.
25. Management Committee of the Australian Therapeutic Trial in Mild Hypertension. Lancet. 1980;1(8181):1261-1267.
26. Amery A, Birkenhäger W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet. 1985;1(8442):1349-1354.
27. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Br Med J. 1985; 291:97-104.
28. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
29. Dahlöf B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338:1281-1285.
30. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J. 1992;304:405-412.
31. Gong L, Zhang W, Zhu Y, et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens. 1996;14:1237-1245.
32. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension [published correction appears in Lancet. 1997;350:1636]. Lancet. 1997;350: 757-764.
33. Liu L, Wang JG, Gong L, et al. Comparison of active treatment and placebo for older patients with isolated systolic hypertension. J Hypertens. 1998;16:1823-1829.
34. Helgeland A. Treatment of mild hypertension: a five year controlled drug trial. Am J Med. 1980;69:725-732.
35. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J. 1986;293:1145-1151.
36. Borhani NO, Mercuri M, Borhani PA, et al. Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS). A randomized controlled trial. JAMA. 1996;276:785-791.
37. PATS Collaborative Group. Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J. 1995;108:710-717.
38. Sprackling ME, Mitchell JRA, Short AH, et al. Blood pressure reduction in the elderly: a randomised controlled trial of methyldopa. Br Med J. 1981;283:1151-1153.
39. Perry HM Jr. Treatment of mild hypertension: preliminary results of a two-year feasibility trial. Circ Res. 1977;40(5 suppl 1):I180-I187.
40. Barraclough M, Joys MD, MacGregor GA, et al. Control of moderately raised blood pressure: report of a co-operative randomized controlled trial. Br Med J. 1973;3:434-436.
41. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effect of treatment on morbidity in hypertension: results in patients with diastolic blood pressure averaging 115-129 mm. Hg. JAMA. 1967;202:116-122.
42. Wolff FW, Lindeman RD. Effects of treatment in hypertension: results of a controlled study. J Chron Dis. 1966;19:227-240.
43. Carter AB. Hypotensive therapy in stroke survivors. Lancet. 1970;1:485-489.
44. Kuramoto K, Matsushita S, Kuwajima I, et al. Prospective study on the treatment of mild hypertension in the aged. Jpn Heart J. 1981;22:75-85.
45. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA. 1979;242:2562-2571.
46. Cashin-Hemphill L, Holmvang G, Chan RC, et al. Angiotensin-converting enzyme inhibition as anti-atherosclerotic therapy: no answer yet. Am J Cardiol. 1999;83:43-47.
47. Neaton JD, Grimm JRH, Prineas RJ, et al. Treatment of mild hypertension study: final results. JAMA. 1993;270:713-724.
48. Casiglia E, Spolaore P, Mazza A, et al. Effecf of 2 different therapeutic approaches on total and cardiovascular mortality in a Cardiovascular Study in the Elderly. Jpn Heart J. 1994;35:589-600.
49. The IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Primary Prevention Study in Hypertension (IPPPSH). J Hypertens. 1985;3:379-392.
50. Wilhelmsen L, Berglund G, Elmfeldt D, et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens. 1987;5:561-572.
51. Wikstrand J, Westergren G, Berglund G, et al. Antihypertensive treatment with metoprolol or hydrochlorothiazide in patients aged 60 to 75 years. Report from a double-blind international multicenter study. JAMA. 1986;255:1304-1310.
52. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338:645-652.
53. Tatti P, Pahor M, Byington RB, et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;21:597-603.
54. European Working Party on High Blood Pressure in the Elderly (EWPHE). An international trial of antihypertensive therapy in elderly patients. Objectives, protocol and organization. Arch Intern Pharmacodyn Thér. 1985;275:300-334.
55. Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens. 1996;9:342-360.
56. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-259.
57. Hedges LV, I Olkin. Statistical Methods for Meta-Analysis. San Diego, CA: Academic Press Inc; 1985.
58. Wang JG, Staessen JA, Gong L, et al. Chinese trial on isolated systolic hypertension in the elderly. Arch Intern Med. 2000;160:211-220.
59. Staessen JA, Thijs L, Birkenhäger WH, et al. Update on the Systolic Hypertension in Europe (Syst-Eur) Trial. Hypertension. 1999;33:1476-1477.
60. Davies MJ. Reactive oxygen species, metallo-proteinases, and plaque stability. Circulation. 1998;97:2382-2383.
61. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitors Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 1995;275:1450-1456.
62. Flather MD, Yusuf S, Køber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet. 2000;355:1575-1581.
63. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-774.
64. The Joint National Committee on Prevention Detection Evaluation and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med. 1997;157:2413-2446.
65. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. Guidelines Subcommittee. J Hypertens. 1999;17:151-183.
66. Moser M. Treating hypertension: calcium channel blockers, diuretics, β-blockers, ACE inhibitors: is there a difference? J Clin Hypertens. 2000;2:301-305.
67. Moser M, Pickering TG, Weber MA. Roundtable discussion: blood pressure lowering by any means, or do specific medications make a difference? J Clin Hypertens. 2001;3:369-375.